INTRODUCTION {#s1}
============

Microglia-mediated neuroinflammation is a prominent and early feature of Alzheimer's disease (AD) \[[@R1]-[@R2]\]. Polarization of resident microglia is a functional dichotomy involving classical M1 and alternative M2 phenotypes \[[@R3]\]. M1 polarized microglia are characterized by an overproduction of inflammatory cytokines including IL-1 and TNF-α. In contrast, M2 polarized microglia are characterized by the release of anti-inflammatory mediators including IL-10 and TGF-β, which leads to regeneration and neuroprotection \[[@R4]-[@R5]\]. Continued polarization towards an M1 phenotype results in inflammation \[[@R6]\]. Therapeutics that promote the differentiation of microglia from an M1 to M2 phenotype could be effective in neuroinflammatory diseases such as AD \[[@R4], [@R7]-[@R8]\].

Low-density lipoprotein receptor-related protein-1 (LRP-1) is an endocytic receptor that is highly expressed on neurons and glial cells \[[@R9]\]. It plays an essential role in the clearance of amyloid-β (Aβ) from the central nervous system \[[@R10]-[@R11]\]. Reduced low-density lipoprotein receptor-related protein (LRP) levels have been observed in AD patients compared to healthy controls \[[@R12]\]. Additionally, increased LRP-1 levels in AD patients were correlated with a later age of disease onset, indicating higher LRP levels might be protective against AD. LRP-1 suppressed the lipopolysaccharide (LPS)-induced inflammatory response *via* the interferon-γ promoter in macrophages \[[@R13]\]. Activation of LRP-1 could modulate microglial inflammation by regulating the JNK and NF-κB signaling pathways \[[@R14]-[@R15]\]. LRP-1 deficiency resulted in down-regulation of M2 marker expression in macrophages and promoted M1 polarization \[[@R16]\]. Thus, LRP-1 may protect against inflammation.

Astaxanthin (ATX) is a naturally carotenoid pigment found in many marine organisms \[[@R17]\]. It has anti-inflammatory and anti-carcinogenic activity as well as neuroprotective effects \[[@R18]-[@R20]\]. ATX induced down-regulation of IL-6 through an NF-κB p65-dependent pathway in activated BV2 microglial cells \[[@R21]\] and inhibited NF-κB activity by down-regulating IKK \[[@R22]\]. We previously demonstrated that ATX protected glutamate-induced cytotoxicity in HT22 cells by attenuating caspase activation and mitochondrial dysfunction, and modulating Akt/GSK-3β signaling \[[@R20]\].

We investigated the effects of ATX on M1/M2 microglia polarization and inflammation. Pretreatment of LPS-stimulated BV2 cells with ATX promoted an M2 neuroprotective phenotype. We observed an increase in the expression of M2 (Arg-1, IL-10, and CD206) and a decrease in the expression of M1 (TNF-α, IL-1β, and CD86) markers. We found that LRP-1 was a target of ATX and demonstrated that the NF-κB and JNK signaling pathways comprise the core mechanisms underlying ATX-mediated suppression of neuroinflammation.

RESULTS {#s2}
=======

LPS differentially induces M1 and M2 marker expression in BV2 cells {#s2_1}
-------------------------------------------------------------------

Reactive polarized microglia are characterized by differential expression of inflammatory cytokines and cell surface markers. To evaluate M1/M2 polarization, we analyzed the expression of M1 and M2 cytokines (TNF-α and IL-1β, and Arg-1 and IL-10, respectively), and surface markers (CD86 and CD206, respectively) in BV2 cells after treatment with LPS (10 ng/mL) for 0, 0.5, 1, 2, or 4 h using quantitative reverse transcription PCR (RT-PCR). We observed a time-dependent increase in M1 marker expression (TNF-α, IL-1β, and CD86) between 0.5 and 4 h in LPS-treated compared to control cells (Figure [1a, 1c, 1e](#F1){ref-type="fig"}) (*P* \< 0.05). In contrast, a time-dependent decrease in the expression of M2 markers was observed between 0.5 and 4 h. Significant decreases in Arg-1 and IL-10 were observed at 1, 2, and 4 h, and in CD206 at 2 h and 4 h compared to untreated control cells (Figure [1b, 1d, 1f](#F1){ref-type="fig"}) (*P* \< 0.05). Thus, LPS induced M1 microglia activation and inhibited M2 polarization in BV2 cells.

![LPS induces alterations in the expression of M1 and M2 markers\
BV2 cells were treated with LPS (10 ng/mL) for the indicated times (0, 0.5, 1, 2, or 4 h). Total RNA was extracted and the expression of M1 markers (TNF-α, IL-1β, and CD86) and M2 markers (Arg-1, IL-10, and CD206) analyzed by RT-PCR. Fold changes in gene expression were quantified relative to β-actin. **a.**, **c.**, **e.** M1 marker expression. **b.**, **d.**, **f.** M2 marker expression. Data are presented as the mean ± SD (*n* = 3). ^\*^*P* \< 0.05 compared to controls.](oncotarget-08-69370-g001){#F1}

ATX suppresses LPS-induced M1 polarization and promotes M2 polarization in BV2 cells {#s2_2}
------------------------------------------------------------------------------------

We investigated the anti-inflammatory effects of ATX at various concentrations (0 to 10 μM) and M1/M2 polarization in LPS-stimulated BV2 cells. ELISA data indicated ATX inhibited LPS-induced TNF-α release from BV2 cells in a dose-dependent manner. The highest inhibition was observed at 10 μM (Figure [2a](#F2){ref-type="fig"}, *P* \< 0.05). Conversely, ATX induced a dose-dependent increase in IL-10 release from BV2 cells (Figure [2b](#F2){ref-type="fig"}, *P* \< 0.05). RT-PCR analysis demonstrated that ATX reduced the expression of M1 markers (TNF-α, IL-1β, and CD86) in a dose-dependent manner (Figure [2c-2e](#F2){ref-type="fig"}). A significant decrease in TNF-α and CD86 was observed at 2.5 to 10 μM, and in IL-1β between 5 and 10 μM compared to LPS-treated control cells (*P* \< 0.05). ATX also induced a dose-dependent increase in the expression of M2 markers (Arg-1, IL-10, and CD206) (Figure [2f-2h](#F2){ref-type="fig"}). A significant increase in IL-10 was observed between 2.5 and 10 μM (IL-10), and in Arg-1 and CD206 at 5 and 10 μM compared to cells treated with LPS alone (*P* \< 0.05). Thus, ATX inhibited LPS-induced M1 microglia activation while promoting M2 polarization in BV2 cells.

![ATX inhibits LPS-induced M1 and promotes M2 polarization in BV2 cells\
**a.**-**b.** BV2 cells were incubated with ATX at the indicated concentrations (0, 2.5, 5, and 10 μM) for 4 h. Cells were then incubated with LPS (10 ng/mL) for 4 h. TNF-α and IL-10 production in the media was examined using ELISA. **c.**-**h.** BV2 cells were incubated with ATX at the indicated concentrations (0, 2.5, 5, and 10 μM) for 4 h. LPS (10 ng/mL) was then added for 4 h. Total RNA was extracted and the expression of M1 (TNF-α, IL-1β, and CD86) and M2 (Arg-1, IL-10, and CD206) markers analyzed by RT-PCR. Fold changes in gene expression were quantified relative to β-actin. **c.**-**e.** M1 markers. **f.**-**h.** M2 markers. Data are presented as the mean ± SD (*n* = 3). ^\*^*P* \< 0.05 indicates a significant difference in the expression of the different markers relative to untreated \[LPS (−)/ATX (−)\] controls. ^\*\*^*P* \< 0.05 indicates a significant difference in the expression of the different markers compared to LPS (+)/ATX (−)-treated cells.](oncotarget-08-69370-g002){#F2}

ATX reverses LPS-induced microglia polarization by inhibiting NF-κB and JNK activation {#s2_3}
--------------------------------------------------------------------------------------

To understand the potential mechanisms by which ATX reversed LPS-induced M1 polarization, we analyzed NF-κB and c-Jun N-terminal kinase (JNK) pathway activation, which functions downstream of LPS stimulation \[[@R23]-[@R24]\]. We examined the phosphorylation of IKKα, IκBα, and NF-κB p65 by western blotting. Pretreatment of LPS-stimulated BV2 cells with ATX reduced the levels of p-IKKα, p-IκBα, and p-p65. The levels of p-IκBα increased after LPS stimulation whereas the levels of IκBα decreased, resulting in the translocation of NF-κB p65 into the nucleus. These effects were reversed by pretreatment with ATX (Figure [3a](#F3){ref-type="fig"}). IκBα/β levels did not change after LPS stimulation in the presence or absence of ATX (Figure [3a](#F3){ref-type="fig"}). Similar effects were observed in band intensity (Figure [3b-3d](#F3){ref-type="fig"}). Under normal conditions, NF-κB p65 was cytoplasmic. Analysis of nuclear and cytosolic extracts from BV2 cells revealed a decrease in p65 translocation from the cytoplasm to the nucleus after pretreatment with ATX (Figure [3a](#F3){ref-type="fig"}). In addition, the level of p-c-Jun was higher after LPS stimulation compared to control cells, and was attenuated upon pretreatment with ATX (Figure [3a, 3e](#F3){ref-type="fig"}). We found that ATX inhibited IKKα, IκBα, p65, and c-Jun phosphorylation in LPS-induced BV2 microglial cells. These results suggested that ATX reversed LPS-induced microglia polarization by inhibiting NF-κB and JNK pathway activation.

![ATX reverses LPS-induced microglia polarization by inhibiting NF-κB and JNK signaling\
BV2 cells were incubated with ATX at the indicated concentrations (0, 2.5, 5, and 10 μM) for 4 h. LPS (10 ng/mL) was then added for 4 h. **a.** Western blot analysis of NF-κB and JNK pathway proteins. **b.** Analysis of the ratio of p-IKKα/p-IKKα/β expression. **c.** Analysis of the ratio of p-IκBα/IκBα expression. **d.** Analysis of the ratio of p-p65/β-actin expression. **e.** Analysis of the ratio of p-c-Jun/total-c-Jun expression. Data are presented as the mean ± SD (*n* = 3). ^\*^*P* \< 0.05 indicates a significant difference in the expression of the different markers relative to untreated \[LPS (−)/ATX (−)\] controls. ^\*\*^*P* \< 0.05 indicates a significant difference in the expression of the different markers compared to LPS (+)/ATX (−)-treated cells.](oncotarget-08-69370-g003){#F3}

ATX reverses the LPS-induced reduction in LRP-1 expression in BV2 cells {#s2_4}
-----------------------------------------------------------------------

Previous studies have found that various stimuli including LPS cause down-regulation of LRP-1 expression, indicating LRP-1 has an essential role in regulating microglia activation \[[@R25]-[@R26]\]. Therefore, we analyzed LRP-1 levels in the presence and absence of ATX. We treated BV2 cells with LPS (10 ng/mL) for the indicated times (0, 0.5, 1, 2, and 4 h) and analyzed LRP-1 mRNA and protein expression by RT-PCR and western blotting. LPS induced a time-dependent decrease in LRP-1 mRNA between 0.5 and 4 h. Significant decreases were observed at 1, 2, and 4 h relative to controls (*P* \< 0.05) (Figure [4a-4c](#F4){ref-type="fig"}). We next examined LRP-1 expression in LPS-stimulated BV2 cells after treatment with ATX at various concentrations ranging from 0 to 10 μM. ATX at concentrations ranging from 2.5 μM to 10 μM reversed the LPS-induced down-regulation of LRP-1 mRNA and protein expression relative to untreated control BV2 cells in a dose-dependent manner (*P* \< 0.05) (Figure [4d-4f](#F4){ref-type="fig"}).

![ATX reverses the LPS-induced reduction in LRP-1 expression in BV2 cells\
**a.**-**c.** BV2 cells were treated with LPS (10 ng/mL) for the indicated times (0, 0.5, 1, 2, and 4 h) and LRP-1 mRNA and protein levels analyzed. Fold changes in LRP-1 expression relative to β-actin are shown. **d**.-**f**. BV2 cells were incubated with ATX at the indicated concentrations (0, 2.5, 5, and 10 μM) for 4 h and then incubated with LPS (10 ng/mL) for 4 h. LRP-1 mRNA and protein levels were analyzed. Data are presented as the mean ± SD (*n* = 3). ^\*^*P* \< 0.05 indicates a significant difference in the expression of the different markers relative to untreated \[LPS (−)/ATX (−)\] controls. ^\*\*^*P* \< 0.05 indicates a significant difference in the expression of the different markers compared to LPS (+)/ATX (−)-treated cells.](oncotarget-08-69370-g004){#F4}

The LRP-1 antagonist receptor-associated protein inhibits M2 polarization by activating NF-κB and JNK signaling {#s2_5}
---------------------------------------------------------------------------------------------------------------

Receptor-associated protein (RAP) is a specialized endoplasmic reticulum (ER) chaperone for LDL receptor family members including LRP-1 \[[@R27]\], which binds to LRP-1 with high affinity and has been widely used as an antagonist of LRP-1 function \[[@R28]\]. To investigate whether RAP regulated ATX-induced M2 microglia polarization, we analyzed the expression of M1 (TNF-α, IL-1β, and CD86) and M2 (Arg-1, IL-10, and CD206) markers in BV2 cells. Pretreatment with RAP (25 nM for 30 min) resulted in an increase in the expression of M1 markers indicating RAP promoted M1 polarization (Figure [5a, 5c, 5e](#F5){ref-type="fig"}). Conversely, RAP reduced the ATX-enhanced expression of M2 markers in BV2 cells (Figure [5b, 5d, 5f](#F5){ref-type="fig"}), indicating RAP inhibited M2 polarization. We examined the effects of RAP on NF-κB and JNK signaling. Upon treatment with LPS and ATX, we observed decreased phosphorylation of IKKα, IκBα, and p65. In contrast, enhanced phosphorylation of IKKα, IκBα, and p-65 was observed upon addition of RAP, indicative of activation of NF-κB signaling (Figure [6a-6d](#F6){ref-type="fig"}). RAP induced an increase in p-c-Jun, which was indicative of activation of JNK signaling (Figure [6a, 6e](#F6){ref-type="fig"}). These results indicated that RAP inhibited ATX-induced M2 microglia polarization by activating NF-κB and JNK signaling.

![RAP inhibits ATX-induced M2 microglia polarization\
BV2 cells were incubated with ATX (10 μM) or RAP (25 nM) for 4 h prior to treatment with LPS (10 ng/mL) for 4 h. Total RNA was extracted and the expression of M1 (TNF-α, IL-1β, and CD86) and M2 (Arg-1, IL-10, and CD206) markers analyzed by RT-PCR. Fold changes in gene expression were calculated relative to β-actin. **a.**, **c.**, **e.** M1 marker expression. **b.**, **d.**, **f.** M2 marker expression. The data are presented as the mean ± SD (*n* = 3). ^\*^*P* \< 0.05 indicates a significant difference in the expression of the different markers compared to LPS (−)/ATX (−)/RAP (−)-treated cells. ^\*\*^*P* \< 0.05 indicates a significant difference compared to LPS (+)/ATX (−)/RAP (−)-treated cells. ^\*\*\*^*P* \< 0.05 indicates a significant difference compared to LPS (+)/ATX (+) /RAP (−)-treated cells.](oncotarget-08-69370-g005){#F5}

![RAP inhibits ATX-induced M2 microglia polarization by promoting NF-κB and JNK activation\
BV2 cells were incubated with ATX (10 μM) or RAP (25 nM) for 4 h prior to treatment with LPS (10 ng/mL) for 4 h. **a.** Analysis of NF-κB and JNK signaling pathway proteins by western blotting. **b.** Analysis of the ratio of p-IKKα/p-IKKα/β expression. **c.** Analysis of the ratio of p-IκBα/IκBα expression. **d.** Analysis of the ratio of p-p65/β-actin expression. **e.** Analysis of the ratio of p-c-Jun/total c-Jun expression. Data are presented as the mean ± SD (*n* = 3). ^\*^*P* \< 0.05 indicates a significant difference in the expression of the different markers compared to LPS (−)/ATX (−)/RAP (−)-treated cells. ^\*\*^*P* \< 0.05 indicates a significant difference compared to LPS (+)/ATX (−)/RAP (−)-treated cells. ^\*\*\*^*P* \< 0.05 indicates a significant difference compared to LPS (+)/ATX (+) /RAP (−)-treated cells.](oncotarget-08-69370-g006){#F6}

Inhibition of NF-κB and JNK signaling attenuates ATX-induced M2 polarization {#s2_6}
----------------------------------------------------------------------------

To confirm that ATX suppressed the proinflammatory response, we inhibited NF-κB activity with BAY11-7082 and JNK activity with SP600125. We examined the expression of M1 (TNF-α, IL-1β, and CD86) and M2 (Arg-1, IL-10, and CD206) markers after treatment with BAY11-7082, which inhibits NF-κB signaling by reducing p-IκBα levels \[[@R29]\]. Pretreatment of BV2 cells with ATX resulted in a decrease in TNF-α mRNA. However, this effect was abolished by pretreatment with BAY11-7082 (10 μM for 30 min). A similar trend was observed in IL-1β and CD86 mRNA expression (Figure [7a, 7c, 7e](#F7){ref-type="fig"}) compared to LPS- and ATX-treated cells (*P* \< 0.05). ATX pretreatment reversed the reduction in Arg-1 mRNA expression. Pretreatment with an NF-κB inhibitor increased Arg-1 mRNA expression compared to control cells. Similar effects were observed in IL-10 and CD206 mRNA expression (Figure [7b, 7d, 7f](#F7){ref-type="fig"}). SP600125 is a cell-permeable small molecule that selectively inhibits JNK isoforms and prevents phosphorylation of c-Jun \[[@R30]\]. SP600125 treatment (10 μM for 30min) increased TNF-α, IL-1β, and CD86 mRNA levels (Figure [7a, 7c, 7e](#F7){ref-type="fig"}), and reduced the levels of Arg-1, IL-10, and CD206, which were elevated in response to ATX pretreatment (Figure [7b, 7d, 7f](#F7){ref-type="fig"}). Inhibition of NF-κB and JNK abolished M1 but enhanced M2 marker expression. Thus, ATX regulated M2 microglia polarization by inhibiting NF-κB and JNK signaling pathway activation.

![Inhibition of NF-κB and JNK signaling attenuates ATX-induced M2 microglia polarization\
BV2 cells were incubated with ATX (10 μM for 4 h), SP600125 (10 μM for 30 min), or Bay11-7082 (10 μM, for 30 min) prior to LPS treatment (10 ng/mL for 4 h). Total RNA was extracted and the expression of M1 (TNF-α, IL-1β, and CD86) and M2 (Arg-1, IL-10, and CD206) markers analyzed by RT-PCR. Fold changes in gene expression were quantified relative to β-actin. **a.**, **c.**, **e.** M1 marker expression. **b.**, **d.**, **f.** M2 marker expression. The data are presented as the mean ± SD (*n* = 3). ^\*^*P* \< 0.05 indicates a significant difference compared to LPS (+)/ATX (−)/SP600125 (−)/Bay11-7082 (−)-treated cells. ^\*\*^*P* \< 0.05 indicates a significant difference compared to LPS (+)/ATX (+)/SP600125 (−)/Bay11-7082(−)-treated cells. ^\*\*\*^*P* \< 0.05 indicates a significant difference compared to LPS (+)/ATX (+)/SP600125 (−)/Bay 11-7082 (−)-treated cells.](oncotarget-08-69370-g007){#F7}

DISCUSSION {#s3}
==========

We investigated whether ATX reversed the M1/M2 polarization of LPS-induced BV2 cells to suppress neuroinflammation through LRP-1. Pretreatment with ATX promoted induced a neuroprotective phenotype by inhibiting proinflammatory M1 and promoting anti-inflammatory M2 polarization in LPS-stimulated BV2 microglial cells. We also elucidated the role LRP-1-dependent NF-κB and JNK inhibition in ATX-induced M2 polarization. Our data suggest that ATX promotes M2 polarization to suppress neuroinflammation in an LRP-1-dependent manner by modulating NF-κB and JNK signaling.

M1 and M2 microglia function is regulated by cytokines and microbial-derived products including LPS \[[@R31]\]. In an *in vitro* microenvironment, LPS and IFNγ promote M1 polarization, while IL-4 and IL-13 promote M2 polarization (Figure [1](#F1){ref-type="fig"}) \[[@R4]\]. M1 microglia release proinflammatory cytokines such as TNF-α, IL-6, and IL-1β to induce an inflammatory response \[[@R32]\]. In contrast, M2 microglia produce Arg1, IL-10, and neurotrophic factors such as nerve growth factor, which attenuate the inflammatory response \[[@R33]\]. The phenotypes are distinguished by specific markers \[[@R34]\]. We found that ATX pretreatment of LPS-treated BV2 cells resulted in down-regulation of M1 (TNF-α, IL-1β, and CD86) and enhanced expression of M2 (Arg-1, IL-10, and CD206) markers (Figure [1](#F1){ref-type="fig"}-[2](#F2){ref-type="fig"}). The neuroprotective effects of ATX resulted, at least in part, from M2 polarization. Treatment of amyloid precursor protein (APP)/PS1 transgenic mice with the small molecule MW-151 attenuated microglial activation and the production of proinflammatory cytokines in the cortex. This resulted in protection from synaptic dysfunction, which has been implicated in learning and memory \[[@R35]\]. Therefore, it might be clinically beneficial to manipulate microglia phenotypes from M1 cytotoxic to M2 neuroprotective through drug treatment or genetic modification.

NF-κB activation is responsible for M1 macrophage polarization and inflammation in response to LPS in BV2 cells. Under normal conditions, the heterodimeric NF-κB subunits p50 and p65 form a complex with the intrinsic inhibitor IκBα in plasma. Phosphorylation of IκB by IKKα leads IκBα degradation, which allows NF-κB nuclear translocation and activation. NF-κB transcriptional activity is regulated by posttranslational modifications such as phosphorylation of p65 \[[@R36]\]. We found that ATX inhibited LPS-induced p65 phosphorylation and nuclear translocation in BV2 cells. The LPS-enhanced levels of p-IκBα and p-IKKα were reduced after pretreatment with ATX (Figure [3a, 3c](#F3){ref-type="fig"}). These results indicated that ATX reversed LPS-induced microglia activation through inhibition of NF-κB and JNK signaling. JNK signaling has a central role in neuroinflammation and contributes to AD. LPS was shown to induce JNK activation in normal microglia, which led to increased production of inflammatory cytokines \[[@R14]\]. We also observed aberrant JNK activation in LPS-induced BV2 cells, which was reversed by pretreatment with ATX (Figure [3a, 3c](#F3){ref-type="fig"}).

Because both the JNK and NF-κB pathways were responsible for microglial activation in LPS-stimulated BV2 cells, we investigated whether inhibition of these pathways could reverse ATX-induced M1/M2 polarization of microglia. Inhibition of the NF-κB and JNK pathways with BAY11-7082 and SP600125 revealed their intrinsic effects on M1/M2 polarization in BV2 cells (Figure [7a-7f](#F7){ref-type="fig"}). ATX inhibited the activation of NF-κB and JNK signaling to suppress neuroinflammation.

Microglial cells in brain tissue from wild-type mice expressed higher levels of LRP-1 \[[@R37]\]. Previous studies have suggested that LRP-1 regulates inflammation and has a protective role in microglia in human adults \[[@R38]\]. Reduced LRP-1 expression and increased levels of proinflammatory chemokines may act synergistically to promote microglial activation \[[@R39]-[@R40]\]. Chuang et al. demonstrated that in the brains of microglial *LRP-1* conditional knockout mice, microglia adopted a proinflammatory phenotype characterized by amoeboid morphology, indicating that LRP-1 may regulate microglial activation \[[@R41]\]. We observed aberrant down-regulation of LRP-1 mRNA and protein levels in LPS-induced BV2 cells, which was reversed by ATX in a dose-dependent manner (Figure [4](#F4){ref-type="fig"}). These results indicate LRP-1 has an important role in ATX-induced M2 polarization. Additional studies are needed to understand the mechanisms underlying ATX-mediated LRP-1 activation in microglia.

The production of cytokines such as TNF-α, IL-6, and IL-1β, is tightly controlled by NF-κB signaling. NF-κB is a master transcriptional regulator of the inflammatory response \[[@R42]\]. Blocking NF-kB activation specifically in microglia has a neuroprotective effect during experimental autoimmune encephalitis \[[@R41]\]. LRP-1 can inhibit inflammation through regulation of NF-κB activity \[[@R40]\]. Additionally, Yang et al. demonstrated that suppression of LRP-1 results in activation of NF-κB and JNK signaling, suggesting that LRP-1 directly regulates signaling pathways that are critical for the inflammatory response in microglial cells \[[@R15]\]. We found that RAP induced phosphorylation of IKKα, IκBα, and p-65 in BV2 cells, which was indicative of NF-κB activation. Consistent with the results of Chuang et al. \[[@R41]\], we demonstrated that RAP promoted NF-κB activation in the presence of inflammatory stimuli. Therefore, we speculated that the interaction between LRP-1 and NF-κB could be important for ATX-mediated inhibition of NF-κB activation. Although a previous study suggested that LRP-1 inhibited NF-κB activation in a MyD88-dependent manner \[[@R41]\], the underlying mechanisms have not been elucidated.

LPS can promote activation of MAPK signaling pathways \[[@R43]\]. Pocivavsek et al. demonstrated that LDL receptor activation reversed glial inflammation *via* JNK activation, and that the anti-inflammatory effects of an apoE mimetic peptide reduced JNK activity \[[@R44]\]. We determined that RAP promoted phosphorylation of c-Jun, consistent with a previous study \[[@R15]\]. These findings support the hypothesis that LRP-1 mediated the anti-inflammatory effects of ATX in LPS-induced BV2 cells. Interactions between the cytoplasmic domains of LRP-1 (LRP-1-ICD) and JNK-interacting proteins regulate JNK signaling \[[@R45]\]. Overexpression of the LRP-1-ICD selectively inhibited activated JNK from translocating into the nucleus, and reduced phosphorylation of c-Jun \[[@R46]\]. Indeed, an LRP-1 agonist attenuated the expression of proinflammatory mediators, while an antagonist had the opposite effect in macrophages \[[@R47]\].

LRP-1 participates in a variety of pathways linked to AD pathogenesis. It regulates endocytosis of ligands including ApoE and Aβ. It also mediates Aβ clearance through cellular uptake followed by lysosomal degradation and/or transcytosis across the blood brain barrier to the circulation and subsequent peripheral clearance \[[@R48]-[@R49]\]. Binding of APP to LRP-1 resulted in increased clearance of APP \[[@R50]\] and deletion of LRP-1 exacerbated Aβ deposition \[[@R10]\]. Dysregulation of LRP-1 has been associated with the aberrant activation or impaired function of the innate immune system in AD. Additionally, the glial activation observed in AD brains may represent a failure of LRP-1 immunomodulatory functions in the presence of chronic insults by Aβ oligomers \[[@R51]\]. Given that LRP-1 functions in both inflammation and Aβ clearance, it may have a key regulatory role in AD.

In summary, ATX elevates LRP-1, which can bind and down-regulate both NF-κB p65 and p-c-Jun, thus preventing the activation of the NF-κB and JNK pathways. The repression of NF-κB and JNK activation reverses LPS-induced M1 microglia polarization, thereby attenuating the neuroinflammatory response. Restoration of LRP-1 expression in microglia may serve as a novel therapeutic approach to combat microglial dysfunction associated with chronic inflammation in neurodegenerative diseases including AD. This study provides a molecular basis for further studies of ATX in LPS-induced microglia inflammatory responses in BV2 cells (Figure [8](#F8){ref-type="fig"}). ATX promotes M2 microglia polarization to suppress neuroinflammation in an LRP-1-dependent manner by inhibiting NF-κB and JNK activation. Therefore, ATX may be an effective therapeutic for AD.

![Schematic showing the proposed anti-inflammatory effects of ATX\
ATX promotes M2 and inhibits M1 polarization in LPS-stimulated BV2 cells by attenuating JNK and NF-κB pathway activation and inflammation through LRP-1. LRP-1 could either directly or indirectly mediate inhibition of inflammatory signaling pathways following LPS stimulation.](oncotarget-08-69370-g008){#F8}

MATERIALS AND METHODS {#s4}
=====================

Chemicals {#s4_1}
---------

ATX was purchased from Sigma-Aldrich (St. Louis, MO, USA). Recombinant mouse RAP was purchased from R&D Systems (Minneapolis, MN, USA). The following primary antibodies were used for western blotting: mouse/rabbit anti-p-IKKα, anti-IKKα/β, anti-p-IκB, anti-IκB, anti-p-p65, anti-p65, anti-p-c-Jun, anti-total-c-Jun, and anti-β-actin. All antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). LPS, the NF-κB inhibitor (BAY 11-7082), and JNK inhibitor (SP600125) were purchased from Sigma-Aldrich. The Nuclear and Cytoplasmic Protein Extraction Reagents and BCA protein assay kit were obtained from Beyotime Biotechnology (Haimen, China). SYBR RT-PCR Kits were purchased from Takara Shuzo (Shiga, Japan).

Cell culture {#s4_2}
------------

BV2 cells are an immortalized murine microglial cell line, which is frequently used as a substitute for primary microglia \[[@R52]\]. BV2 cells were cultured in DMEM (HyClone, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA, USA), 100 U/mL penicillin, and 100 ug/mL streptomycin at 37°C in a humidified atmosphere containing 5% CO~2~ and 95% air. Cells were pretreated with or without ATX (0 to 10μM) for 4 h and then co-incubated with LPS 10 ng/mL for 4 h to evaluate the protective effects of ATX.

ELISA {#s4_3}
-----

BV2 cells were incubated with ATX in the indicated concentrations (0, 2.5, 5, and 10 μM) for 4 h. LPS (10 ng/mL) was then added and the cells incubated for 4 h. TNF-α and IL-10 production were analyzed in BV2 cell conditioned media 24 h after incubation using an ELISA kit (Dakewe, Shenzhen, China). The levels of TNF-α and IL-10 were quantified using the manufacturer's protocol.

Quantitative RT-PCR {#s4_4}
-------------------

BV2 cells were seeded into six-well plates and treated as indicated. Total RNA was extracted using the Trizol reagent according to the manufacturer's instructions. RT-PCR were performed using the One-Step RT-PCR System (Applied Biosystems, Foster City, CA, USA). One microgram of RNA template was reverse-transcribed using a Prime Script RT Master Mix Kit (Clontech, Mountain View, CA, USA). RT-PCR was performed using 2 μL of cDNA solution in a 20 μL reaction mixture containing 10 μL of SYBR Premix Ex Taq II, 0.8 μL of the forward primer, 0.8 μL of the reverse primer, and 6 μL ddH~2~O. Relative mRNA expression was assessed using the comparative ^ΔΔ^Ct method. Β-actin was used as an internal standard. The RT-PCR primers are shown in Table [1](#T1){ref-type="table"}.

###### Primers for RT-PCR.

  Gene      Forward(5′-3′)             Reverse (5′-3′)
  --------- -------------------------- --------------------------
  LRP-1     ACTATGGATGCCCCTAAAACTTG    GCAATCTCTTTCACCGTCACA
  TNF-α     CATCTTCTCAAAATTCGAGTGAC    TGGGAGTAGACAAGGTACAACCC
  Arg-1     CGCCT TTCTCAAAAGGACAG      CCAGCTCTT CATTG G C TTTC
  IL-1β     TGTGCAAGTGTCTGAAGCAGC      TGGAAGCAGCCCTTCATCTT
  IL-10     GCTCTTACTGACTGGCATGAG′     CGCAGCTCTAGGAGCATGTG
  CD206     CTTCGGGCCTTTGGAATAAT       TAGAAGAGCCCTTGGGTTGA
  CD86      ACGATGGACCCCAGATGCACCA     GCGTCTCCACGGAAACAGCA
  β-actin   GG CATC GT G ATGGACTC CG   GCTG GAAGGT GGA CAGCGA

Preparation of nuclear and cytosolic fractions {#s4_5}
----------------------------------------------

Cells were homogenized in PER-Mammalian Protein Extraction Buffer (Pierce Biotechnology, Rockford, IL, USA) containing protease inhibitor cocktail I and 1 mM phenylmethylsulfonyl fluoride. Cytosolic fractions were prepared by centrifugation at 15,000 × g for 10 min at 4°C. Nuclear and cytoplasmic extracts from BV2 cells were prepared using the NE-PER nuclear and cytoplasmic extraction reagents (Pierce Biotechnology).

Western blotting {#s4_6}
----------------

BV2 cells were seeded onto six-well plates and treated as indicated. The cells were then harvested and lysates centrifuged at 12,000 × g for 15 min at 4°C. Supernatants was collected and total protein levels measured using the BCA protein assay kit (Beyotime Biotechnology). Equal amounts of total protein were separated by SDS-PAGE and transferred to PVDF membranes (Millipore). The membranes were incubated at room temperature for 1 h in blocking buffer and then incubated with the primary rabbit monoclonal antibodies (Cell Signaling Technology). Finally, the membranes were incubated with HRP-linked secondary antibodies and blots developed using the ECL reagent. After exposure to X-ray film, protein bands were imaged using a UV imaging system. Band intensities were quantified using the ImageJ software. β-actin was used as a loading control.

Statistical analysis {#s4_7}
--------------------

All data are expressed as the mean ± standard deviation (SD). Statistical analyses were performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). Multiple groups were compared using analysis of variance followed by post-hoc Fisher's least significant difference testing when appropriate. A *P* \< 0.05 was considered significant.
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